Myeloma and other plasma cell disorders account for 10 - 15% of the haematological malignancies. Significant progress has been made over the last few years in our understanding of these diseases and in their therapy, resulting in notable improvment in symptom control and survival.
This comprehensive text examines the molecular and biological background of these diseases, the clinical aspects and investigations, and developments in therapy.